Reshaping the Obesity Market Landscape GLP-1s, including widely recognized brand names Wegovy, Mounjaro, and Zepbound, have demonstrated profound weight-loss efficacy, often in the range of 1520% and are set to become the largest-selling drug class globally
Whilst the use of DPP-4 inhibitors may theoretically support weight loss in the treatment of obesity through increasing the half-life of endogenous GLP-1, weight loss associated with their use is clinically insignificant (0.160.64 kg) [29], and as such their use in obesity is not explored further in this manuscript
Figure 3 6 Conclusion In summary, tirzepatide, a dual agonist of the GLP-1 and GIP receptors, shows promising potential for the management of obesity-related OSAS by promoting weight loss, improving metabolic function, and modulating inflammatory pathways
If youre a guy looking to stack GLP-1 with the rest of the longevity toolkit, this is the only partner reviewed here designed around that combination
Inject slowly and steadily for improved comfort and less post-injection leakage